(Q40551742)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

title

Use of CFU-GM assay for prediction of human maximum tolerated dose of a new antitumoral drug: Yondelis (ET-743) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

Susana G Gómez

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Glynn Faircloth

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Beatriz Albella

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

issue

5-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

page(s)

671-674

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

Preserved long-term repopulation and differentiation properties of hematopoietic grafts subjected to ex vivo expansion with stem cell factor and interleukin 11

20 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0887-2333%2803%2900139-5

7 January 2021

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity

1 reference

https://api.crossref.org/works/10.1016%2FS0887-2333%2803%2900139-5

7 January 2021

Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation

1 reference

https://api.crossref.org/works/10.1016%2FS0887-2333%2803%2900139-5

7 January 2021

Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning

1 reference

https://api.crossref.org/works/10.1016%2FS0887-2333%2803%2900139-5

7 January 2021

In vivo-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and erythroid hematopoietic progenitors from human, murine, and canine marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0887-2333%2803%2900139-5

7 January 2021

Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0887-2333%2803%2900139-5

7 January 2021

Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-2333%2803%2900139-5

7 January 2021

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

1 reference

https://api.crossref.org/works/10.1016%2FS0887-2333%2803%2900139-5

7 January 2021

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-2333%2803%2900139-5

7 January 2021

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-2333%2803%2900139-5

7 January 2021

10.1016/S0887-2333(03)00139-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14599461%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference